Encouraged by CDH13 suppression for imatinib-resistant cells in vitro, we next investigated their therapeutic efficacy in vivo using a BCR-ABL1 independent resistant CML xenograft model. This evidence concerns the gene CDH13 and chronic myelogenous leukemia, BCR-ABL1 positive.